Merck’s investigational antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) met the primary endpoint of overall survival in the Phase 3 TroFuse-015 trial in patients with locally advanced, unresectable or metastatic gastroesophageal adenocarcinoma. The final analysis showed a statistically significant survival improvement compared with physician’s choice of treatment in patients who had received at least two prior lines of systemic therapy.
Overall survival results were generally consistent across subgroups regardless of TROP2 expression status, Merck said. The trial did not meet its secondary endpoint of progression-free survival as assessed by blinded independent central review. Objective response favored sac-TMT, but the difference was not formally tested under the prespecified analysis plan.
The global, open-label study enrolled 473 patients and randomly assigned them to receive sac-TMT or one of four treatments selected by their physician: trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. Merck said the safety profile was consistent with earlier studies of sac-TMT and that no new safety signals were observed.
Kelun-Biotech developed the TROP2-directed drug, and Merck holds exclusive rights to develop, manufacture and commercialize it outside Greater China. TroFuse-015 is the second Phase 3 trial in Merck’s TroFuse program to report positive results; the program has 18 ongoing global Phase 3 trials across multiple tumor types.
The broader program includes studies in breast, bladder, ovarian and non-small cell lung cancers and is testing sac-TMT both alone and in combination with immunotherapies. Merck plans to present the TroFuse-015 results at an upcoming medical meeting and share the data with regulatory authorities.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!